Brookline Capital Management Weighs in on BIOX Q4 Earnings

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) – Investment analysts at Brookline Capital Management reduced their Q4 2025 earnings estimates for Bioceres Crop Solutions in a research report issued to clients and investors on Tuesday, November 12th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn $0.09 per share for the quarter, down from their previous forecast of $0.13. The consensus estimate for Bioceres Crop Solutions’ current full-year earnings is $0.31 per share.

Several other research analysts also recently weighed in on BIOX. Oppenheimer lowered their price objective on shares of Bioceres Crop Solutions from $16.00 to $13.00 and set an “outperform” rating on the stock in a report on Monday, October 21st. Roth Mkm cut their price target on Bioceres Crop Solutions from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Canaccord Genuity Group upgraded Bioceres Crop Solutions to a “strong-buy” rating in a report on Friday, July 19th. Canaccord Genuity Group decreased their price target on Bioceres Crop Solutions from $10.00 to $9.50 and set a “buy” rating for the company in a report on Wednesday. Finally, Lake Street Capital dropped their price objective on Bioceres Crop Solutions from $25.00 to $13.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $12.13.

Bioceres Crop Solutions Price Performance

Shares of NASDAQ:BIOX opened at $6.42 on Thursday. Bioceres Crop Solutions has a twelve month low of $5.71 and a twelve month high of $14.05. The stock’s 50 day moving average is $7.66 and its 200-day moving average is $9.83. The company has a quick ratio of 0.86, a current ratio of 1.24 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $403.50 million, a price-to-earnings ratio of 330.67 and a beta of 0.49.

Bioceres Crop Solutions (NASDAQ:BIOX) last issued its earnings results on Monday, November 11th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.11). The firm had revenue of $92.60 million during the quarter, compared to the consensus estimate of $117.15 million. Bioceres Crop Solutions had a net margin of 0.53% and a return on equity of 0.68%. During the same period in the previous year, the firm earned ($0.07) earnings per share.

Institutional Investors Weigh In On Bioceres Crop Solutions

Several large investors have recently made changes to their positions in BIOX. Oppenheimer & Co. Inc. bought a new position in Bioceres Crop Solutions during the first quarter valued at about $139,000. Lazard Asset Management LLC purchased a new stake in shares of Bioceres Crop Solutions during the 1st quarter worth approximately $212,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Bioceres Crop Solutions in the 2nd quarter worth approximately $472,000. Oak Family Advisors LLC lifted its stake in Bioceres Crop Solutions by 1.9% in the second quarter. Oak Family Advisors LLC now owns 64,925 shares of the company’s stock valued at $728,000 after purchasing an additional 1,208 shares during the last quarter. Finally, Ping Capital Management Inc. bought a new position in Bioceres Crop Solutions during the second quarter valued at $448,000. 17.68% of the stock is owned by hedge funds and other institutional investors.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.